Gadopiclenol
Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium. Gadopiclenol was approved for medical use in the United States in September 2022. Names 
Gadopiclenol is the international nonproprietary name (INN). Pharmacology  
Gadopiclenol has a higher relaxivity compared with standard gadolinium-based contrast agents (GBCAs). The higher relaxivity allows for a lower dose of gadopiclenol, reducing the total amount of gadolinium administered to the patient while preserving imaging quality. Gadopiclenol was approved by the FDA with a recommended dose of 0.05 mmol/kg for adults and pediatric patients aged 2 years and older. This is half the dose of standard macrocyclic GBCAs, which have a recommended dose of 0.1 mmol/kg. References

External links 
 
 

MRI contrast agents
Pyridines
Heterocyclic compounds with 2 rings
Carboxylic acids
Polyols
Amides
Gadolinium compounds